

EMMESSAR BIOTECH & NUTRITION LTD						
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2017						Rs. In lacs
Particulars	Current 3 months ended 31.03.2017	Preceeding 3 months ended	9 months period ended 31.12.2016	Corresponding Qtr ended 31.03.2016	Current Year ended 31.03.2017	Previous year ended 31.03.2016
	Audited (1)	Unaudited (2)	Unaudited (3)	Audited (3)	Audited (4)	Audited (5)
PART I						
01) Income from Operations						
(a) Net Sales / Income from operations (Net of Excise Duty)	72.49	79.21	190.81	51.24	263.30	197.44
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Total Income	72.49	79.21	190.81	51.24	263.30	197.44
02) Expenditure						
(a) Cost of material consumed	13.23	1.12	64.58	0.96	77.81	53.56
(b) Purchase of Stock-trade	5.92	6.61	12.82	0.00	18.74	5.48
(c) Change in inventories of Finished goods	25.08	45.26	(25.79)	52.61	(0.71)	37.16
(d) Employee Benefit Expenses	10.11	11.14	28.85	8.55	38.96	31.10
(e) Depreciation & amortisation of Assets	0.35	0.27	0.80	1.62	1.15	2.72
(f) Other Expenditure	18.82	4.86	87.96	2.37	106.78	69.04
(g) Expenditure (a to f)	73.51	69.26	169.22	66.11	242.73	199.06
03) Profit / (loss) from Operations before Other Income, Interest & Exceptional items(1 - 2)	(1.02)	9.95	21.59	(14.87)	20.57	(1.62)
04) Other Income	32.74	32.01	64.79	16.08	97.53	25.87
05) Profit / (Loss) before Interest and Exceptional Items (3 + 4)	31.72	41.96	86.38	1.21	118.10	24.25
06) Interest	0.00	0.00	0.00	0.00	0.00	0.00
07) Profit / (Loss) after Interest but before Exceptional Items (5 - 6)	31.72	41.96	86.38	1.21	118.10	24.25
08) Exceptional Items	0.00	0.00	0.00	0.00	0.00	(92.17)
09) Profit / (Loss) from Ordinary Activities Before Taxation (7 + 8)	31.72	41.96	86.38	1.21	118.10	(67.92)
10) Tax Expense (Deferred tax)	0.06	0.00	0.00	(21.39)	0.06	(21.39)
11) Net Profit / (Loss) from Ordinary Activities after Taxation (9 - 10)	31.66	41.96	86.38	22.60	118.04	(46.53)
12) Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13) Net Profit / (Loss) for the period (11-12)	31.66	41.96	86.38	22.60	118.04	(46.53)
14) Share of profit / loss of associates	NA	NA	NA	NA	NA	NA
15) Minority Interest	NA	NA	NA	NA	NA	NA
16) Net profit / (loss) for the period (13 + 14 + 15)	31.66	41.96	86.38	22.60	118.04	(46.53)
17) Paid-up Equity Share Capital (Face Value of the share)	499.61	499.61	499.61	499.61	499.61	499.61
18) Reserves excluding Revaluation Reserve as per Balance Sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	0.00
19) Earning per Shares	0.63	0.84	1.73	0.45	2.36	(0.93)
a) Basic & diluted EPS before Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)						
b) Basic & diluted EPS after Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)	0.63	0.84	1.73	0.45	2.36	(0.93)



PART II

A. PARTICULARS OF SHAREHOLDINGS

	2017	2016	2015	2014	2013	2012
1) Public Shareholding						
- No. of Shares	2090314	2032385	2032385	2020385	2090314	2020385
- Percentage of Shareholding	41.84	40.68	40.68	40.44	41.84	40.44
2) Promoters & Promoter Group Shareholding						
a) Pledged / Encumbered						
- No. of Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as % of the total Share Capital of the Company)						
b) Non Encumbered						
- No. of Shares	2905786	2963715	2963715	2975715	2905786	2975715
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of shares (as % of the total Share Capital of the Company)	58.16	59.32	59.32	59.56	58.16	59.56

Particulars

Three Months ended 31.03.2017

B. INVESTORS COMPLAINTS

Pending at the beginning of the quarter	NIL
Received during the quarter	NIL
Disposed off during the quarter	NIL
Remaining unresolved at the end of the quarter	NIL

- * The above results were reviewed by the Audit Committee of the Board of Directors.
- * The above Audited Results were taken on record at the meeting of the Board of Directors held on 24th May, 2017.
- * The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures
- * During this quarter the Company has operated in 2 segments.

Mumbai
24-May-17

By order of the Board
MSR Ayyangar
Managing Director



EMMESSAR BIOTECH & NUTRITION LTD

Quarter and Year ended Segment wise Revenue Results and Capital Employed under Clause 41 of the Listing Agreement.						
[Rs. In Lakhs]						
	Current 3 months ended 31.03.2017	Preceding 3 months ended 31.12.2016	Corresponding Qtr ended 31.03.2016	9 months previous period ended 31.12.2016	Current year 31.03.2017	Previous year 31.03.2016
	Audited	Unaudited	Audited	Audited	Audited	Audited
1. Segment Revenue (Net Sales / Income)						
a. Healthcare	22.99	22.70	4.24	64.41	87.40	48.67
b. Fine Chemicals	49.50	56.51	47.00	126.40	175.90	148.77
c. Others	34.23	32.01	14.58	64.79	97.52	25.87
Total:	105.22	111.22	65.82	255.60	360.82	223.31
Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales / Income from Operations	105.22	111.22	65.82	255.60	360.82	223.31
2. Segment Results (Profit / Loss) before Tax and Interest						
a. Healthcare	13.85	14.92	1.72	39.10	52.95	31.23
b. Fine Chemicals	2.96	9.52	(6.60)	40.44	43.40	23.94
c. Others	34.23	32.01	16.08	64.79	97.52	25.87
Total:	51.04	56.45	11.20	144.33	193.87	81.04
Less:						
Interest	0.00	0.00	0.00	0.00	0.00	0.00
Other Unallocable Expenditure net off Unallocable Income	19.32	14.49	9.99	57.95	75.77	56.79
Total Profit / (loss) before Tax	31.72	41.96	1.21	86.38	118.10	24.25
3. Capital Employed (Segment Assets - Segment Liabilities)						
a. Healthcare	7.51	14.76	17.28	14.76	7.51	17.28
b. Fine Chemicals	57.42	68.91	34.78	68.91	57.42	34.78
c. Others	(20.70)	9.32	(16.94)	9.32	(20.70)	(16.94)
Total:	44.23	92.99	35.12	92.99	44.23	35.12

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on May 24, 2017

Mumbai
24-May-17


 By order of the Board
 MSR Ayyangar
 Managing Director



EMMESSAR BIOTECH & NUTRITION LTD			
Statements of Assets & Liabilities			
(Rs. In Lakhs)			
	Particulars	As at 31.03.2017	As at 31.03.2016
A	EQUITY AND LIABILITIES		
1	SHAREHOLDER'S FUNDS:		
	(a) Share Capital	499.61	499.61
	(b) Reserves & Surplus	(290.66)	(408.70)
	Sub-total Shareholder's funds	208.95	90.91
2	Non-current Liabilities		
	(a) Other Long-term Liabilities	61.42	61.42
	(b) Long Term Provisions	5.14	5.07
	Sub-total Non-current liabilities	66.56	66.49
3	Current Liabilities		
	(a) Trade payables	20.47	20.07
	(b) Other current Liabilities	17.34	44.01
	(c) Short-term provisions	8.58	5.89
	Sub-total Current Liabilities	46.38	69.97
	TOTAL EQUITY AND LIABILITIES	321.89	227.37
B	ASSETS		
1	Non-current Assets		
	(a) Property, Plant & Equipment	152.80	73.01
	(b) Deferred Tax Assets	11.29	11.35
	(c) Long-term loans and advances	29.44	17.48
	Sub-total Non-current Assets	193.54	101.84
2	Current Assets		
	(a) Current Investments	0.63	0.60
	(b) Inventories	31.82	35.81
	(c) Trade Receivables	4.09	36.48
	(d) Cash & Cash equivalents	31.94	42.67
	(e) Short-term loans and advances	59.87	9.97
	Sub-total Current Assets	128.36	125.53
	TOTAL ASSETS	321.89	227.37

[Handwritten Signature]

